Study Links Vaping to Irregular Heartbeats in Mice

Nov.03.2022
Study Links Vaping to Irregular Heartbeats in Mice
A study on e-cigarette liquids causing heart rhythm disruption in mice is criticized for its lack of relevance to humans.

A newspaper has reported on a study claiming that electronic cigarette liquid can disrupt heart rhythms, but has failed to highlight that the study was conducted on mice and involved toxic doses. An expert on tobacco reduction has pointed out that the only information this study provides is that "pet mouse owners should not allow their mice to use electronic cigarettes.


According to The Independent, a new study has found that using e-cigarette fluids containing certain ingredients can cause heart rhythm irregularities, thereby increasing the risk of heart attacks.


A recent study published in Nature Communications suggests that e-cigarettes and their individual components can cause irregular heart rhythms and conduction defects in mice. The researchers conducted electrocardiogram tests on mice after acute inhalation of e-cigarette vapors. They argue that "our findings suggest that the chemical composition of e-cigarettes may increase cardiac risk by inducing changes that promote arrhythmogenesis and stimulate autonomic reflexes.


Experts in tobacco harm reduction and e-cigarettes quickly criticized the study. Professor Jacob George, Head of Cardiovascular Medicine and Therapeutics at the University of Dundee Medical School, said: "The metabolism of mice is very different from that of humans, and to be honest, any inference to long-term human health effects are at best speculative. If this were indeed true, given the large number of e-cigarette users worldwide, we would have expected to see a dramatic increase in cases of arrhythmia, which we have not seen in clinical practice.


The controversial nature of e-cigarettes brings into question the preliminary and speculative science surrounding its potential impact on human health, including the effects of nicotine on blood vessels. However, large-scale observational studies of users of nicotine replacement therapy have shown no increase in heart events. These findings should not deter those seeking to quit smoking from attempting e-cigarettes or nicotine replacement therapy. This early-stage preclinical research requires further clinical work before it can be considered directly related to human health.


Professor Peter Hajek, director of the Tobacco Dependence Research Department at Queen Mary University of London, added that "in this study, mice were exposed to aerosols from e-cigarette solvents with and without nicotine, as well as acrolein (a chemical that may be produced due to overheating) in e-cigarette liquid. Such exposure was associated with short-term changes in the mice's electrocardiograms and an increase in heart rate.


When talking about applying the results of this study to humans, there are several issues to consider. Electronic cigarette users are unlikely to be exposed to significant levels of acrolein since overheated e-liquid produces an unpleasant taste that people tend to avoid. While the study used exposure levels to other chemicals that humans can tolerate, the same dose may cause significant pain in much smaller mammals with more sensitive olfactory systems and varying tolerances to medication. It would be strange if animals exposed to aversive stimuli did not show a cardiovascular response. The reason for using mice in this study remains unclear. When experiments cannot be conducted on humans, animal models may be used, but comparing heart rate and electrocardiograms for electronic cigarette components and human smoking reactions is not without hurdles.


Professor Kevin McConway, Honorary Professor of Applied Statistics at The Open University in the UK, continues to criticize and has released a detailed statement saying: "As a statistician and not a biologist, I am unable to comment on the physiological details of this study. However, in my view, most aspects of the statistical analysis of the experimental results are reliable, and the study provides good evidence that certain components of e-cigarettes do indeed affect some aspects of mouse heart function when the mice are exposed to these components in the way done in this study. Nevertheless, while I believe that investigating the potential harmful effects of e-cigarette components is certainly worthwhile, and I also believe that animal experiments can play a role in this work, this work cannot answer some important questions.


I don't believe any knowledgeable commentator has suggested that using e-cigarettes is without risk. The important question is how the harm of using e-cigarettes compares to the harm that would result if the person did not use them. This, of course, depends on what the person would do if they did not use e-cigarettes. If they are a traditional smoker and e-cigarettes help them quit, then using e-cigarettes would prevent greater harm from their previous smoking habit. Other studies have shown that e-cigarettes can effectively help people quit smoking and are often more effective than nicotine replacement therapy like patches or gum. So, when used by smokers, the real question is not whether e-cigarettes are completely harmless, but whether they are safer than continuing to smoke or using other methods to quit, which may be less effective. This new study does not shed light on that question, and there is no evidence in its findings to suggest that using e-cigarettes is as harmful as smoking regular cigarettes, even in mice.


For those who are not yet smokers, electronic cigarette companies say it may be different. However, people still need to consider whether using electronic cigarettes may lead to other dangerous habits, such as using different drugs.


To the best of my understanding, this study has the potential to distinguish the effects of different components in e-cigarettes to some extent, which is an advantage. For example, this could lead to the development of safer e-cigarettes. However, as noted by the researchers, the reactions to various chemicals observed in mice may not necessarily apply to humans, even though this study specifically looks at several components of e-cigarettes and their potential effects on mice. Therefore, there is still a lot of work to be done and all relevant factors must be taken into consideration.


In addition, the study used a very small number of female mice - only four - and these mice did not come into contact with most of the substances involved. This means that, as the researchers have themselves acknowledged, some of the potential conclusions about gender differences are not based on evidence. Finally, these mice were (of course) completely unfamiliar with e-cigarettes, and the researchers note that the effects may be very different for individuals who have experience with e-cigarettes or tobacco use.


Dr. Adam Jacobs, Senior Director of Biostatistics at Premier Research, provided commentary on the study, stating "This study suggests that mice exposed to e-cigarette aerosol in a closed space for 90 minutes experience short-term changes in heart rhythm. While the long-term effects of these changes are not yet clear, it seems prudent for pet owners to avoid exposing their rodents to e-cigarettes. For humans, while e-cigarettes cannot be considered completely safe, there is a significant amount of evidence showing it to be much safer than smoking combustible cigarettes. Therefore, smokers who switch from traditional cigarettes to e-cigarettes will greatly reduce their health risks.


Statement:


The content of this article is compiled from third-party information and is only intended for industry exchange and learning purposes.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of its content. The translation of this article is only intended for industry communication and research purposes.


Due to limitations in the translator's skills, the translated article may not fully express the same meaning as the original text. Please refer to the original text for accuracy.


2FIRSTS remains completely aligned with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, or foreign-related statements and positions.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us to request removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

2Firsts Exclusive Analysis | RLX Q2 Revenue Rises 14.8%, Company Takes Control of Western European Distributor and Expands Multi-Category Strategy
2Firsts Exclusive Analysis | RLX Q2 Revenue Rises 14.8%, Company Takes Control of Western European Distributor and Expands Multi-Category Strategy
business accounting for 68.5% of sales. A new controlling investment in a Western European distributor and plans to scale modern oral nicotine pouches point to a broader international strategy spanning channels and multiple product categories.
Special Report
Aug.14
South Korea Constitutional Court Upholds Volume-Based E-Liquid Tax, With Challenged Rates at KRW 370 and KRW 628 per Milliliter
South Korea Constitutional Court Upholds Volume-Based E-Liquid Tax, With Challenged Rates at KRW 370 and KRW 628 per Milliliter
South Korea's Constitutional Court has upheld fixed taxes on nicotine-containing e-cigarette liquids based on solution volume, ruling that challenged provisions imposing KRW 370 per milliliter in individual consumption tax and KRW 628 per milliliter in tobacco consumption tax do not violate the Constitution. The cases stemmed from historical disputes involving importers that reported nicotine as being extracted from tobacco stems rather than leaves. South Korea has since broadened its tobacco definition to include synthetic nicotine, while current tax laws provide reduced rates for certain products not derived from tobacco.
Sep.18
Product | JNR Launches Crown Shisha 100K for International Wholesale, Pairing 58ml Capacity With Triple-Mesh DTL Design
Product | JNR Launches Crown Shisha 100K for International Wholesale, Pairing 58ml Capacity With Triple-Mesh DTL Design
JNR released the Crown Shisha 100K on August 14, 2026, positioning the ultra-high-capacity disposable around a direct-to-lung (DTL) e-shisha experience. The device combines a 58ml e-liquid capacity, triple 1.0Ω mesh coils and a 1,300mAh rechargeable battery, with JNR claiming up to 100,000 puffs. Adjustable airflow, battery and e-liquid status displays, a leather-style exterior and a shisha-inspired sound effect further differentiate the product. JNR is currently promoting the device through international wholesale and distribution channels, while a specific first retail market has not been disclosed.
Aug.31
Australia’s One Nation Proposes 75% Tobacco Tax Cut, Says Lower Prices Could Hit Illicit Market
Australia’s One Nation Proposes 75% Tobacco Tax Cut, Says Lower Prices Could Hit Illicit Market
Australia’s One Nation party has proposed cutting tobacco excise by 75%, arguing that lower legal cigarette prices could narrow the gap with illicit tobacco and reduce demand for black-market products. The proposal comes as Australia continues expanding enforcement against illicit tobacco supply chains through border controls, retail inspections and organised-crime investigations. Supporters argue high taxes have contributed to illicit-market growth, while opponents warn that lower tobacco prices could undermine public-health goals. The proposal is a party policy position and has not been adopted by the Australian government.
Aug.18
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
From Nicotine Salts to Cocrystals: China’s Shenzhen Huabao institute explores a more stable form for sustained nicotine release
From Nicotine Salts to Cocrystals: China’s Shenzhen Huabao institute explores a more stable form for sustained nicotine release
China-based Shenzhen Huabao Collaborative Innovation Technology Research Institute Co., Ltd. has filed a patent application for a nicotine-ascorbic acid cocrystal, exploring a new solid-state form of nicotine. The patent proposes applications across e-liquids, heated tobacco sticks, oral tobacco, chewing tobacco and snuff. In nicotine pouch tests disclosed in the filing, cocrystal formulations showed less than a 6% decline in nicotine content after three months of accelerated storage and a release profile combining early-stage release with sustained delivery over 60 minutes. The filing reflects exploration of nicotine forms beyond conventional nicotine base and nicotine salts.
Aug.13